Nexalin™ technology is a patented breakthrough of Dr. Katsnelson’s life’s work. The continued advancement in the Nexalin-related technologies is one of the goals of Kalaco Scientific, Inc. This advancement will include various therapies for different indications as well as making technological advances. Kalaco will seek to patent the technological advances.

Kalaco’s regulatory approvals include: FDA clearance for the use of the Nexalin technology for Depression, Insomnia and Anxiety; no other indications are currently authorized in the United States.

	In the European Union, the Nexalin technology is approved for relief of musculoskeletal pain as well as depression, insomnia and anxiety.
	In Switzerland, Kalaco has received the approval and acceptance of the CE Marking for relief of musculoskeletal pain and the treatment of depression, anxiety and insomnia.
	In Russia, Kalaco has approval of the Nexalin devices for use in medical practice.
	Kalaco has been issued patents on this Nexalin technology in the United States, Australia, Russia, Canada, South Africa, and Taiwan.
	In Australia, Kalaco has received approval from the Therapeutic Goods Administration (TGA) - The equivalent of the United States FDA - for the relief of musculoskeletal pain, as well as the treatment of anxiety, depression, and insomnia. Kalaco has received the official trademark certificate for "Nexalin."